(Q37813081)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

review article

1 reference

title

Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author

Christopher T Tallman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Alon Z Weizer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jeffrey S Montgomery

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

28 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

published in

World Journal of Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

59-71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00345-010-0617-4

17 January 2020

exact match

0 references

cites work

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

21 January 2018

Bladder cancer, 1996.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Provider treatment intensity and outcomes for patients with early-stage bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Clinical outcome of primary versus secondary bladder carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Clinical outcomes of primary bladder carcinoma in situ in a contemporary series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette-Guérin (Danish 1331 strain).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

17-year follow-up of a randomized prospective controlled trial of adjuvant intravesical doxorubicin in the treatment of superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study wit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Intravesical Instillation of Mitomycin-C in 242 Patients with Superficial Bladder Cancer at High Risk of Recurrence: Long-Term Results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-010-0617-4

Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in si

21 January 2018

1 reference

12 December 2020

Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods

1 reference

12 December 2020

A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival

1 reference

12 December 2020

High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG)

1 reference

12 December 2020

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer

1 reference

12 December 2020

Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial

1 reference

12 December 2020

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study

1 reference

12 December 2020

Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin

1 reference

12 December 2020

Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer

1 reference

12 December 2020

Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

1 reference

12 December 2020

Cancer statistics, 2010

1 reference

12 December 2020

Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer geni

1 reference

12 December 2020

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

12 December 2020

Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation

1 reference

12 December 2020

Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours

1 reference

12 December 2020

T1 GIII bladder cancer. Management with transurethral resection only

1 reference

12 December 2020

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study

1 reference

12 December 2020

Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy

1 reference

12 December 2020

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy

1 reference

12 December 2020

Treated natural history of superficial bladder cancer

1 reference

12 December 2020

Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results

1 reference

12 December 2020

Low-dose instillation therapy with bacille Calmette-Guérin Tokyo 172 strain after transurethral resection: historical cohort study

1 reference

12 December 2020

Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup

1 reference

12 December 2020

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials

1 reference

12 December 2020

Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.

1 reference

12 December 2020

Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?

1 reference

12 December 2020

Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance

1 reference

12 December 2020

The health economics of bladder cancer: a comprehensive review of the published literature.

1 reference

12 December 2020

Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

1 reference

12 December 2020

Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ

1 reference

12 December 2020

Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience

1 reference

12 December 2020

Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy

1 reference

12 December 2020

Long-term maintenance bacille Calmette-Guérin therapy in high-grade superficial bladder cancer

1 reference

12 December 2020

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

1 reference

12 December 2020

Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations

1 reference

12 December 2020

Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette-Guerin therapy for carcinoma in situ of the bladder

1 reference

12 December 2020

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

1 reference

12 December 2020

The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy

1 reference

12 December 2020

Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup

1 reference

12 December 2020

The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?

1 reference

12 December 2020

10.1007/S00345-010-0617-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21113783%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference